Publication
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Othman Al-Sawaf, Can Zhang, Mohammad S Esfahani, Chih Long Liu, Sandra Robrecht, Eugen Tausch, Anke Schilhabel, Matthias Ritgen, Christof Schneider, Martin Peifer, Moritz Fürstenau, Carsten Utoft Niemann, Arnon P Kater, John F Seymour, Brenda Chyla, Yanwen Jiang, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Ash A Alizadeh, David M Kurtz, Kirsten Fischer
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Measurable residual disease (MRD) status after limited-duration treatment for chronic lymphocytic leukemia (CLL) strongly predicts survival times and is considered a surrogate end point. However, most prognostic indices, including the International Prognostic Index (CLL-IPI), rely solely…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available